全文获取类型
收费全文 | 46053篇 |
免费 | 2492篇 |
国内免费 | 1273篇 |
专业分类
耳鼻咽喉 | 877篇 |
儿科学 | 782篇 |
妇产科学 | 320篇 |
基础医学 | 2829篇 |
口腔科学 | 461篇 |
临床医学 | 5716篇 |
内科学 | 8974篇 |
皮肤病学 | 478篇 |
神经病学 | 2530篇 |
特种医学 | 1048篇 |
外科学 | 4476篇 |
综合类 | 8604篇 |
一般理论 | 2篇 |
预防医学 | 3198篇 |
眼科学 | 181篇 |
药学 | 4699篇 |
39篇 | |
中国医学 | 3741篇 |
肿瘤学 | 863篇 |
出版年
2024年 | 92篇 |
2023年 | 681篇 |
2022年 | 1596篇 |
2021年 | 2068篇 |
2020年 | 1703篇 |
2019年 | 1489篇 |
2018年 | 1478篇 |
2017年 | 1516篇 |
2016年 | 1805篇 |
2015年 | 1749篇 |
2014年 | 3988篇 |
2013年 | 3703篇 |
2012年 | 3381篇 |
2011年 | 3627篇 |
2010年 | 2841篇 |
2009年 | 2398篇 |
2008年 | 2156篇 |
2007年 | 2095篇 |
2006年 | 1762篇 |
2005年 | 1440篇 |
2004年 | 1107篇 |
2003年 | 951篇 |
2002年 | 693篇 |
2001年 | 640篇 |
2000年 | 557篇 |
1999年 | 518篇 |
1998年 | 379篇 |
1997年 | 309篇 |
1996年 | 319篇 |
1995年 | 290篇 |
1994年 | 273篇 |
1993年 | 214篇 |
1992年 | 201篇 |
1991年 | 174篇 |
1990年 | 196篇 |
1989年 | 161篇 |
1988年 | 139篇 |
1987年 | 123篇 |
1986年 | 106篇 |
1985年 | 118篇 |
1984年 | 131篇 |
1983年 | 81篇 |
1982年 | 96篇 |
1981年 | 78篇 |
1980年 | 88篇 |
1979年 | 67篇 |
1978年 | 47篇 |
1977年 | 52篇 |
1976年 | 40篇 |
1974年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
《Anaesthesia and Intensive Care Medicine》2019,20(8):426-429
Plasticity enables alterations in transmission in nociceptive systems. It is this plasticity in the nervous system that can alter the linear relation between noxious stimuli and the perception of pain and is important in the switch from acute to chronic pain. In this way, a number of CNS mechanisms can alter neuronal activity, leading to abnormal ongoing and stimulus-evoked pains due to peripheral and central changes. Peripheral nerves can become sensitized, spinal cord neurons can be rendered hyperexcitable and ascending projections to higher centres can further trigger changes in descending controls from the midbrain and brainstem. Together, these changes, all of which appear to involve reversible physiological and pharmacological plasticity, can alter the relationship between an applied stimulus and the perceived response and so lead to persistent pain states. 相似文献
33.
目的本研究以护理结局分类(NOC)为基础,筛选符合慢性心力衰竭患者的相关护理结局,由此构建具有专科专病特点的慢性心力衰竭患者护理结局评价表。方法成立研究核心小组,应用文献回顾法、专家函询法确定护理结局分类指标,并进行统计学分析,最终建立慢性心力衰竭护理结局分类评价表。结果通过研究,确定慢性心力衰竭护理结局中包含4个领域、8个一级指标、68个二级指标。4个领域分别是生理健康、功能健康、健康知识和行为、心理社会健康。一级指标中包含心脏泵血功能、活动耐力、社会支持、抑郁水平等。二级指标中包含心脏指数、血压、呼吸困难、情绪波动大、步行距离、步行速度等68个指标。统计学分析中:第一、二轮函询专家的积极系数分别为90%、100%,专家权威系数为0.895,专家意见协调程度(P<0.05)。结论本研究成功建立慢性心力衰竭护理结局分类评价表,有助于临床护士用于评价护理措施的有效性,也使其成为一种标准化语言,便于应用到护理电子信息系统中进行绩效测算等。但是本研究不足之处是未能将该研究进行临床实证,未能进一步确认其有效性。 相似文献
34.
35.
36.
Treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted by drug delivery to the back of the eye. In recent years, concerted efforts in drug delivery have been made to prolong the residence time of drugs injected in the vitreous humor of the eye. Our previous studies demonstrated that poly(ortho ester) (POE) nanoparticles were biodegradable/biocompatible and were capable of long-term sustained release. The objective of the present study was to investigate the safety and localization of POE nanoparticles in New Zealand white rabbits and C57BL/6 mice after intravitreal administration for the treatment of chronic posterior ocular diseases. Two concentration levels of POE nanoparticles solution were chosen for intravitreal injection: 1.5?mg/ml and 10?mg/ml. Our results demonstrate that POE nanoparticles were distributed throughout the vitreous cavity by optical coherence tomography (OCT) examination 14 days post-intravitreal injection. Intraocular pressure was not changed from baseline. Inflammatory or adverse effects were undetectable by slit lamp biomicroscopy. Furthermore, we demonstrate that POE nanoparticles have negligible toxicity assessed at the cellular level evidenced by a lack of glia activation or apoptosis estimation after intravitreal injection. Collectively, POE nanoparticles are a novel and nontoxic as an ocular drug delivery system for the treatment of posterior ocular diseases. 相似文献
37.
38.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
39.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
40.
Bimal Bhindi Christine M. Lohse Phillip J. Schulte Ross J. Mason John C. Cheville Stephen A. Boorjian Bradley C. Leibovich R. Houston Thompson 《European urology》2019,75(5):766-772